These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 16725269)
1. Cancer-related anaemia management in the 21st century. Pronzato P Cancer Treat Rev; 2006; 32 Suppl 2():S1-3. PubMed ID: 16725269 [TBL] [Abstract][Full Text] [Related]
2. Every 3 weeks dosing with darbepoetin alfa: A new paradigm in anaemia management. Vansteenkiste JF Cancer Treat Rev; 2006; 32 Suppl 2():S11-5. PubMed ID: 16725268 [TBL] [Abstract][Full Text] [Related]
4. Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer. Smith RE; Jaiyesimi IA; Meza LA; Tchekmedyian NS; Chan D; Griffith H; Brosman S; Bukowski R; Murdoch M; Rarick M; Saven A; Colowick AB; Fleishman A; Gayko U; Glaspy J Br J Cancer; 2001 Apr; 84 Suppl 1(Suppl 1):24-30. PubMed ID: 11308271 [TBL] [Abstract][Full Text] [Related]
5. Anaemia in cancer patients: pathophysiology, incidence and treatment. Bokemeyer C; Oechsle K; Hartmann JT Eur J Clin Invest; 2005 Dec; 35 Suppl 3():26-31. PubMed ID: 16281955 [TBL] [Abstract][Full Text] [Related]
6. Darbepoetin alfa for chemotherapy-induced anemia: evolution to extended dosing intervals. Vansteenkiste J; Wauters I Expert Rev Anticancer Ther; 2007 Oct; 7(10):1347-55. PubMed ID: 17944560 [TBL] [Abstract][Full Text] [Related]
7. A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy. Glaspy J; Jadeja JS; Justice G; Kessler J; Richards D; Schwartzberg L; Rigas J; Kuter D; Harmon D; Prow D; Demetri G; Gordon D; Arseneau J; Saven A; Hynes H; Boccia R; O'Byrne J; Colowick AB Br J Cancer; 2001 Apr; 84 Suppl 1(Suppl 1):17-23. PubMed ID: 11308270 [TBL] [Abstract][Full Text] [Related]
8. Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy. Demetri GD Br J Cancer; 2001 Apr; 84 Suppl 1(Suppl 1):31-7. PubMed ID: 11308272 [TBL] [Abstract][Full Text] [Related]
9. Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy. Wauters I; Vansteenkiste J Expert Rev Anticancer Ther; 2012 Nov; 12(11):1383-90. PubMed ID: 23113603 [TBL] [Abstract][Full Text] [Related]
10. RETRA: evaluating the transfusion rate with darbepoetin alfa 500 µg every 3 weeks in anaemic cancer patients receiving chemotherapy. Eisterer W; Hussl C; Erb H; Haslbauer F; Sormann S; Braun S; Jaeger C Curr Med Res Opin; 2011 Feb; 27(2):355-63. PubMed ID: 21166611 [TBL] [Abstract][Full Text] [Related]
11. Chemotherapy-induced anemia: the story of darbepoetin alfa. Vansteenkiste J; Wauters I; Elliott S; Glaspy J; Hedenus M Curr Med Res Opin; 2013 Apr; 29(4):325-37. PubMed ID: 23323876 [TBL] [Abstract][Full Text] [Related]
12. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia. Cersosimo RJ; Jacobson DR Ann Pharmacother; 2006 Jan; 40(1):58-65; quiz 169-70. PubMed ID: 16332942 [TBL] [Abstract][Full Text] [Related]
13. The effectiveness of darbepoetin alfa administered every 3 weeks on hematologic outcomes and quality of life in older patients with chemotherapy-induced anemia. Boccia R; Lillie T; Tomita D; Balducci L Oncologist; 2007 May; 12(5):584-93. PubMed ID: 17522247 [TBL] [Abstract][Full Text] [Related]
14. European guidelines for the management of chemotherapy-induced anaemia and health economic aspects of treatment. Repetto L; Moeremans K; Annemans L; Cancer Treat Rev; 2006; 32 Suppl 2():S5-9. PubMed ID: 16725267 [TBL] [Abstract][Full Text] [Related]
15. Erythropoiesis-stimulating agents: favorable safety profile when used as indicated. Nowrousian MR; Dunst J; Vaupel P Strahlenther Onkol; 2008 Mar; 184(3):121-36. PubMed ID: 18330508 [TBL] [Abstract][Full Text] [Related]
16. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. ; Glaspy J; Vadhan-Raj S; Patel R; Bosserman L; Hu E; Lloyd RE; Boccia RV; Tomita D; Rossi G J Clin Oncol; 2006 May; 24(15):2290-7. PubMed ID: 16710026 [TBL] [Abstract][Full Text] [Related]
17. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies. Case AS; Rocconi RP; Kilgore LC; Barnes MN Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064 [TBL] [Abstract][Full Text] [Related]
18. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. Schwartzberg LS; Yee LK; Senecal FM; Charu V; Tomita D; Wallace J; Rossi G Oncologist; 2004; 9(6):696-707. PubMed ID: 15561813 [TBL] [Abstract][Full Text] [Related]
19. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Aapro MS; Link H Oncologist; 2008; 13 Suppl 3():33-6. PubMed ID: 18458123 [TBL] [Abstract][Full Text] [Related]
20. Addition of darbepoetin alfa to dose-dense chemotherapy: results from a randomized phase II trial in small-cell lung cancer patients receiving carboplatin plus etoposide. Nagel S; Kellner O; Engel-Riedel W; Guetz S; Schumann C; Gieseler F; Schuette W Clin Lung Cancer; 2011 Jan; 12(1):62-9. PubMed ID: 21273182 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]